Summary
Boston Scientific Corporation (BSX) has filed an 8-K report on February 4, 2026, to announce its financial results for the fourth quarter and full year ended December 31, 2025. The primary driver of this filing is the accompanying press release, furnished as Exhibit 99.1, which details the company's operational performance and financial condition for the periods mentioned. Investors should refer to this press release for specific figures and commentary regarding revenue, profitability, and any forward-looking statements. While the 8-K itself is procedural, the attached press release is critical for understanding BSX's recent performance. This filing serves as the official notification of the release of these important financial details. It's important to note that the information furnished under Item 2.02 is not considered "filed" for regulatory purposes, meaning it doesn't carry the same liability under Section 18 of the Exchange Act. However, it remains the primary source for investors to obtain the latest financial updates from the company.
Key Highlights
- 1Boston Scientific (BSX) announced fourth quarter and full year 2025 financial results on February 4, 2026.
- 2The results are detailed in a press release furnished as Exhibit 99.1 to the 8-K filing.
- 3Investors should consult Exhibit 99.1 for specific financial performance metrics and operational commentary.
- 4The filing does not contain new material financial statements beyond what is in the press release.
- 5Information furnished under Item 2.02 is not deemed 'filed' for Section 18 of the Exchange Act purposes.
- 6This report serves as official notification of the release of Q4 and FY2025 earnings.